KTKimihito Tachikawa

Kimihito Tachikawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kimihito Tachikawa has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Photoselective Vaporization of the Prostate on Renal Function: A Pressure Flow Study‐Based Analysis

    by Kimihito Tachikawa, Yuki Kyoda, Kohei Hashimoto, Ko Kobayashi, Toshiaki Tanaka, Naoya Masumori

    Objectives: This study assessed changes in renal function from baseline to 6 months after photoselective vaporization of the prostate (PVP). Methods: Among 117 consecutive patients who underwent PVP at our institution between November 2020 and September 2024, 88 patients with complete baseline and 6‐month postoperative blood sampling and pressure flow study (PFS) data were included in the analysis. The primary endpoints were the changes in serum creatinine (sCr) and the estimated glomerular filtration rate (eGFR) from baseline to 6 months postoperatively. Secondary endpoints included changes in urodynamic parameters and clinical outcomes from baseline to 6 months postoperatively. An exploratory group comparison was performed between patients with and without an increase in eGFR of ≥ 5 mL/min/1.73 m 2 . Results: Overall, median sCr and eGFR showed no significant changes, with sCr remaining at 0.93–0.92 mg/dL and eGFR unchanged at 61.7 mL/min/1.73 m 2 ( p = 0.59 and p = 0.29, respectively). Clinical and urodynamic outcomes improved significantly, including a decrease in median Bladder Outlet Obstruction Index (BOOI) from 54.4 to 13.4 ( p < 0.001). Eleven patients (12.5%) met the exploratory eGFR improvement criterion. Compared with the remaining patients, they had a lower baseline eGFR and higher proportions of CKD stage ≥ 3, preoperative catheterization or clean intermittent catheterization, and phasic detrusor overactivity ( p = 0.015, p = 0.0027, p = 0.033, and p = 0.0019, respectively). Conclusions: Overall renal function did not significantly change at 6 months after PVP. The exploratory findings may provide preliminary support for considering PVP in patients with impaired renal function who otherwise meet established indications for surgery; however, they do not establish a renal protective effect and require prospective validation.

  • Open Access

    Urinary HSP90 as a non-invasive biomarker of active tubular injury in kidney transplant recipients: A multicenter prospective study

    by Kimihito Tachikawa, Toshiaki Tanaka, Takeshi Maehana, Tetsuya Shindo, Yuki Kyoda, Kohei Hashimoto, Hayato Nishida, Hiroshi Kitamura, Takahiro Tsuji, Naoya Masumori

  • Open Access

    Which characteristics are associated with changes in medication status for lower urinary tract symptoms among patients with prostate cancer receiving external beam radiotherapy?

    by Yuki Kyoda, Kohei Hashimoto, Atsushi Takahashi, Takeshi Maehana, Kimihito Tachikawa, Takashi Muranaka, Shuichi Kato, Tomoyo Kurisu, Fumimasa Fukuta, Takahiro Kirisawa, et al.

    Background: We clarified the predictive factors for changes in the status of medications for lower urinary tract symptoms (LUTS) 2 years after local radiotherapy for nonmetastatic prostate cancer. Materials and methods: We retrospectively included patients who underwent local external radiotherapy for nonmetastatic prostate cancer in 8 institutions between April 2001 and March 2016. Patients were divided into the medication and no-medication group based on the use of drugs for LUTS before radiotherapy. We defined improvement of LUTS as when the patient did not require medication for LUTS at 24 months after radiotherapy in the medication group and as deterioration when medication was required in the no-medication group. Logistic regression analysis was used to evaluate predictive factors for changes in medication status. Results: Altogether, 505 patients were divided into a no-medication group (n = 352) and a medication group (n = 153). The number of patients with deterioration and improvement in LUTS was 49 (14%) and 36 (23%), respectively. In the multivariate analysis, the predictive variables for deterioration were the International Prostate Symptom Score (≥8; odds ratio [OR], 2.21; p = 0.014) and the biopsy Gleason score (≤3 + 4 = 7; OR, 2.430; p = 0.008) in the no-medication group, whereas those for improvement were age (p = 0.002), the quality of life score (p = 0.028), and a positive biopsy core rate (≥50%; OR, 2.530; p = 0.027) in the medication group. Conclusions: These predictive factors for changes in the status of medications for LUTS at 2 years after external radiotherapy may help determine the definitive therapy for nonmetastatic prostate cancer.


  • Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real‐world clinical practice in Japan, SCCOP study 19‐01

    by Kimihito Tachikawa, Yuki Kyoda, Fumimasa Fukuta, Ko Kobayashi, Naoya Masumori

    Objective: To evaluate the efficacy and safety of vibegron in patients with overactive bladder (OAB) in real‐world clinical practice in Japan.Methods: This multicenter, prospective, non‐controlled study consecutively enrolled patients with OAB determined by an OAB symptom score (OABSS) of three points or more and a question 3 (urgency) score of two points or more. A total of 212 patients from 43 institutions were recruited from January 2019 through March 2020. Vibegron, 50 mg, was administrated daily for 8 weeks as first‐line monotherapy (first‐line group, FL), monotherapy switching from antimuscarinics (post‐antimuscarinic group, PA) or mirabegron (post‐mirabegron group, PM) and combination therapy with antimuscarinics (add‐on group). The OABSS was collected at baseline and every 2 weeks. Adverse events were recorded at every visit.Results: Of the 212 patients registered, 188 (male 76, female 112) were eligible for analysis (124 in the FL group, 27 in PA, 29 in PM, and eight in the add‐on group). The add‐on group was excluded from further analysis due to its small number. The OABSS (mean ± SD) showed significant improvement in all groups (FL; 8.8 ± 2.5, 3.8 ± 2.8, PM; 9.4 ± 2.2, 4.5 ± 4.0, PM; 8.9 ± 2.5, 4.7 ± 3.3 at 0 and 8 weeks, respectively). The overall incidence of adverse events was 25%. No grade 3 or higher adverse events were observed.Conclusions: In the real‐world clinical setting, vibegron is effective and well‐tolerated by OAB patients, including those switching therapy from antimuscarinics and mirabegron.